Beneficial Changes in Apolipoprotein Concentrations After Bariatric Surgery in Obese Women

Figures

• 

  Figure 1. Flow chart of the study.

• 

  Figure 2. (A) Apolipoprotein distribution in blood plasma of patients. The radii are proportional to the median apolipoprotein concentration in a group (depicted as numbers around the circles and horizontal bars in Figure 3, Figure 4 and Figure 5). (B) ApoB/ApoA1 ratio in blood plasma of the patients. Lean subjects (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with the accompanying metabolic syndrome (n = 32); 0 m—0 months (onset of the experiment); 12 m—12 months after the onset of the experiment. Significance markers (p < 0.05): a—vs. Lean (onset); b—vs. Obese MetSx- (onset); c—vs. Obese MetSx+ (onset); *—statistically significant coefficient (p < 0.05).

• 

  Figure 3. Apolipoprotein concentrations in blood plasma of patients. (A) Apolipoprotein A1; (B) apolipoprotein A2; (C) apolipoprotein B. Lean subjects (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with the accompanying metabolic syndrome (n = 32); 0 m—0 months (onset of the experiment); 3, 6, and 12 m—3, 6, and 12 months after the onset of the experiment; a—difference vs. Lean at 0 m (p < 0.05); b—difference vs. Obese MetSx- at 0 m (p < 0.05); c—difference vs. Obese MetSx+ at 0 m (p < 0.05); #—difference of Obese MetSx- vs. Obese MetSx+ within a time point. *—statistically significant coefficient (p < 0.05).

• 

  Figure 4. Apolipoprotein concentrations in blood plasma of patients. (A) Apolipoprotein C1; (B) apolipoprotein C3; (C) apolipoprotein D. Lean subjects (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with accompanying metabolic syndrome (n = 32); 0 m—0 months (onset of the experiment); 3, 6, and 12 m—3, 6, and 12 months after the onset of the experiment; a—difference vs. Lean at 0 m (p < 0.05); b—difference vs. Obese MetSx- at 0 m (p < 0.05); c—difference vs. Obese MetSx+ at 0 m (p < 0.05); *—statistically significant coefficient (p < 0.05).

• 

  Figure 5. Apolipoprotein concentrations in blood plasma of patients. (A) Apolipoprotein E; (B) apolipoprotein H; (C) apolipoprotein J. Lean subjects (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with accompanying metabolic syndrome (n = 32); 0 m—0 months (onset of the experiment); 3, 6, and 12 m—3, 6, and 12 months after the onset of the experiment; a—difference vs. Lean at 0 m (p < 0.05); b—difference vs. Obese MetSx- at 0 m (p < 0.05); c—difference vs. Obese MetSx+ at 0 m (p < 0.05); #—difference of Obese MetSx- vs. Obese MetSx+ within a time point. *—statistically significant coefficient (p < 0.05).

• 

  Figure 6. Pearson correlation coefficients presented in the form of a heatmap. Blue shading—positive correlation; red shading—negative correlation. (A) Lean at 0 m; (B) Obese MetSx- at 0 m; (C) Obese MetSx+ at 0 m. Lean subjects (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with accompanying metabolic syndrome (n = 32); 0 m—0 months (onset of the experiment); *—correlation statistically significant (p < 0.05).

• 

  Figure 7. Pearson correlation coefficients presented in the form of a heatmap. Blue shading—positive correlation; red shading—negative correlation. (A) Obese MetSx- at 12 m; (B) Obese MetSx+ at 12 m (n = 20); Obese MetSx-—obese patients without metabolic syndrome (n = 20); Obese MetSx+—obese patients with accompanying metabolic syndrome (n = 32); 12 m—12 months after the onset of the experiment; *—correlation statistically significant (p < 0.05).